bioAffinity Technologies ... (BIAF)
bioAffinity Statistics
Share Statistics
bioAffinity has 15.58M shares outstanding. The number of shares has increased by 33.69% in one year.
| Shares Outstanding | 15.58M |
| Shares Change (YoY) | 33.69% |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 11.04M |
| Failed to Deliver (FTD) Shares | 72.78K |
| FTD / Avg. Volume | 0.75% |
Short Selling Information
The latest short interest is 115.47K, so 0.63% of the outstanding shares have been sold short.
| Short Interest | 115.47K |
| Short % of Shares Out | 0.63% |
| Short % of Float | 1.05% |
| Short Ratio (days to cover) | 1 |
Valuation Ratios
The PE ratio is -1.25 and the forward PE ratio is -1.07. bioAffinity's PEG ratio is 0.06.
| PE Ratio | -1.25 |
| Forward PE | -1.07 |
| PS Ratio | 1.2 |
| Forward PS | 0.6 |
| PB Ratio | 4.33 |
| P/FCF Ratio | -1.55 |
| PEG Ratio | 0.06 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for bioAffinity.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.87, with a Debt / Equity ratio of 0.58.
| Current Ratio | 0.87 |
| Quick Ratio | 0.86 |
| Debt / Equity | 0.58 |
| Debt / EBITDA | -0.18 |
| Debt / FCF | -0.21 |
| Interest Coverage | -96.82 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $164.25K |
| Profits Per Employee | $-158.59K |
| Employee Count | 57 |
| Asset Turnover | 1.44 |
| Inventory Turnover | 216.73 |
Taxes
| Income Tax | 11.65K |
| Effective Tax Rate | -0.13% |
Stock Price Statistics
The stock price has increased by -82.69% in the last 52 weeks. The beta is 3.47, so bioAffinity's price volatility has been higher than the market average.
| Beta | 3.47 |
| 52-Week Price Change | -82.69% |
| 50-Day Moving Average | 0.55 |
| 200-Day Moving Average | 1.3 |
| Relative Strength Index (RSI) | 48.25 |
| Average Volume (20 Days) | 9.69M |
Income Statement
In the last 12 months, bioAffinity had revenue of 9.36M and earned -9.04M in profits. Earnings per share was -0.73.
| Revenue | 9.36M |
| Gross Profit | 3.38M |
| Operating Income | -8.95M |
| Net Income | -9.04M |
| EBITDA | -8.33M |
| EBIT | -8.94M |
| Earnings Per Share (EPS) | -0.73 |
Balance Sheet
The company has 1.11M in cash and 1.5M in debt, giving a net cash position of -395.9K.
| Cash & Cash Equivalents | 1.11M |
| Total Debt | 1.5M |
| Net Cash | -395.9K |
| Retained Earnings | -53.64M |
| Total Assets | 6.51M |
| Working Capital | -409.81K |
Cash Flow
In the last 12 months, operating cash flow was -7.26M and capital expenditures 0, giving a free cash flow of -7.26M.
| Operating Cash Flow | -7.26M |
| Capital Expenditures | 0 |
| Free Cash Flow | -7.26M |
| FCF Per Share | -0.59 |
Margins
Gross margin is 36.09%, with operating and profit margins of -95.64% and -96.56%.
| Gross Margin | 36.09% |
| Operating Margin | -95.64% |
| Pretax Margin | -96.43% |
| Profit Margin | -96.56% |
| EBITDA Margin | -88.98% |
| EBIT Margin | -95.64% |
| FCF Margin | -77.6% |
Dividends & Yields
BIAF does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for BIAF is $6, which is 1124.5% higher than the current price. The consensus rating is "Buy".
| Price Target | $6 |
| Price Target Difference | 1124.5% |
| Analyst Consensus | Buy |
| Analyst Count | 1 |
Scores
| Altman Z-Score | -13.29 |
| Piotroski F-Score | 4 |